Filing Flows › Celularity (CELU) › R&D spending
Celularity (CELU) R&D spending by quarter
Celularity's R&D spending was $2.0M in Q2 2026 (second quarter 2026), -32% from Q1 2026. Over the last 7 quarters it ranged from $2.0M (Q2 2026) to $4.6M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $2.0M | -32% | -39% |
| Q1 2026 | $3.0M | -11% | -20% |
| Q4 2025 | $3.3M | -27% | -13% |
| Q3 2025 | $4.6M | +37% | — |
| Q2 2025 | $3.4M | -10% | — |
| Q1 2025 | $3.7M | -3% | — |
| Q4 2024 | $3.8M | — | — |
Q2 2026 at a glance
Celularity, Q2 2026: revenue $5.4M (-5% year over year), operating margin -78.0%, net earnings $706K, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Celularity's R&D spending?
Celularity's R&D spending was $2.0M in Q2 2026 (second quarter 2026), -32% from Q1 2026.
How has Celularity's R&D spending changed?
Over the last 7 quarters it ranged from $2.0M (Q2 2026) to $4.6M (Q3 2025).